pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2020-30-1-61-68pulmo-1281Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL STUDIESПротективное действие беклометазона дипропионата при моделировании хронической обструктивной болезни легкихThe protective effect of beclomethasone dipropionate in the modeling of chronic obstructive pulmonary diseasehttps://orcid.org/0000-0003-4678-3904ТитоваО. Н.TitovaO. N.

Титова Ольга Николаевна – д. м. н., профессор, директор Научно-исследовательского института пульмонологии

197022, Санкт-Петербург, ул. Льва Толстого, 6–8тел.: (812) 338-78-40 

Ol'ga N. Titova, Doctor of Medicine, Professor, Director of Pulmonology Research Institute

ul. L'va Tolstogo 6–8, Saint-Petersburg, 197089tel.: (812) 338-78-40 

titova-on@mail.ruhttps://orcid.org/0000-0002-1166-9717КузубоваН. А.KuzubovaN. A.

Кузубова Наталия Анатольевна – д. м. н., заместитель директора Научно-исследовательского института пульмонологии

197022, Санкт-Петербург, ул. Льва Толстого, 6–8тел.: (812) 338-66-16 

Nataliya A. Kuzubova, Doctor of Medicine, Deputy Director, Pulmonology Research Institute

ul. L'va Tolstogo 6–8, Saint-Petersburg, 197089tel.: (812) 338-66-16 

kuzubova@mail.ruhttps://orcid.org/0000-0001-6887-0166ЛебедеваЕ. С.LebedevaE. S.

Лебедева Елена Сергеевна – к. б. н., ведущий научный сотрудник Научно-исследовательского института пульмонологии

197022, Санкт-Петербург, ул. Льва Толстого, 6–8тел.: (812) 338-78-20 

Elena S. Lebedeva, Candidate of Biology, Leading Researcher, Pulmonology Research Institute

ul. L'va Tolstogo 6–8, Saint-Petersburg, 197089tel.: (812) 338-78-20 

osmelena@mail.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П.Павлова» Министерства здравоохранения Российской ФедерацииРоссияAcademician I.P.Pavlov First Federal Saint-Petersburg State Medical University, Healthcare Ministry of RussiaRussian Federation2020210420203016168Copyright © Титова О.Н., Кузубова Н.А., Лебедева Е.С., 20202020Титова О.Н., Кузубова Н.А., Лебедева Е.С.Titova O.N., Kuzubova N.A., Lebedeva E.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/1281хроническая обструктивная болезнь легкихингаляционные глюкокортикостероидыбеклометазона дипропионатвоспалениеchronic obstructive pulmonary diseaseinhaled glucocorticosteroidsBeclomethasone dipropionateinflammationПубликация осуществлена при финансовой поддержке компании «Кьези Фармасьютикалс». Мнение автора может не совпадать с позицией компании. Компания «Кьези Фармасьютикалс» не несет ответственности за возможные нарушения авторских прав и иных прав третьих лиц в результате публикации и распространения данной информации.This publication is supported by Chiesi Pharmaceuticals. The author's opinion could differ from the position of the company. Chiesi Pharmaceuticals is not responsible for any possible pyracy and other violations of stakeholders' rights and right of other third parties resulted from this publication and the information spread.ReferencesGlobal Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2019 Report. Available at: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018WMS.pdf [Accessed: September 6, 2019].Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2019 Report. Available at: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018WMS.pdf [Accessed: September 6, 2019].Rutgers S.R., Postma D.S., ten Hacken N.H. et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax. 2000; 55 (1): 12–18. DOI:10.1136/thorax.55.1.12.Rutgers S.R., Postma D.S., ten Hacken N.H. et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax. 2000; 55 (1): 12–18. DOI: 10.1136/thorax.55.1.12.Barnes P.J. Inhaled corticosteroids in COPD: a controversy. Respiration. 2010; 80 (2): 89–95. DOI: 10.1159/000315416.Barnes P.J. Inhaled corticosteroids in COPD: a controversy. Respiration. 2010; 80 (2): 89–95. DOI: 10.1159/000315416.Aisanov Z., Avdeev S., Arkhipov V. et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 183–187. DOI: 10.2147/COPD.S153770.Aisanov Z., Avdeev S., Arkhipov V. et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 183–187. DOI: 10.2147/COPD.S153770.Agusti A., Fabbri L.M., Singh D. et al. Inhaled corticosteroids in COPD: friend or foe? Eur. Respir. J. 2018; 52 (6). pii: 1801219. DOI: 10.1183/13993003.01219-2018.Agusti A., Fabbri L.M., Singh D. et al. Inhaled corticosteroids in COPD: friend or foe? Eur. Respir. J. 2018; 52 (6). pii: 1801219. DOI: 10.1183/13993003.01219-2018.Cataldo D., Derom E., Liistro G. et al. Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 2089–2099. DOI: 10.2147/COPD.S164259.Cataldo D., Derom E., Liistro G. et al. Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 2089–2099. DOI: 10.2147/COPD.S164259.Crim C., Calverley P.M.A., Anderson J.A. et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur. Respir. J. 2009; 34 (3): 641–647. DOI: 10.1183/09031936.00193908.Crim C., Calverley P.M.A., Anderson J.A. et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur. Respir. J. 2009; 34 (3): 641–647. DOI: 10.1183/09031936.00193908.Vanfleteren L., Fabbri L.M., Papi A. et al. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 3971–3981. DOI: 10.2147/COPD.S185975.Vanfleteren L., Fabbri L.M., Papi A. et al. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 3971–3981. DOI: 10.2147/COPD.S185975.Thomas B.J., Porritt R.A., Hertzog P.J. et al. Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon. Sci. Rep. 2014; 4: 7176. DOI: 10.1038/srep07176.Thomas B.J., Porritt R.A., Hertzog P.J. et al. Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon. Sci. Rep. 2014; 4: 7176. DOI: 10.1038/srep07176.Contoli M., Pauletti A., Rossi M.R. et al. Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD. Eur. Respir. J. 2017; 50 (4): 1700451. DOI: 10.1183/13993003.00451-2017.Contoli M., Pauletti A., Rossi M.R. et al. Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD. Eur. Respir. J. 2017; 50 (4): 1700451. DOI: 10.1183/13993003.00451-2017.Pavord I.D., Lettis S., Locantore N. et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax. 2016; 71 (2): 118–125. DOI: 10.1136/thoraxjnl-2015-207021.Pavord I.D., Lettis S., Locantore N. et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax. 2016; 71 (2): 118–125. DOI: 10.1136/thoraxjnl-2015-207021.Bafadhel M., Pavord I.D., Russell R.E.K. Eosinophils in COPD: just another biomarker? Lancet Respir. Med. 2017; 5 (9): 747–759. DOI: 10.1016/S2213-2600(17)30217-5.Bafadhel M., Pavord I.D., Russell R.E.K. Eosinophils in COPD: just another biomarker? Lancet Respir. Med. 2017; 5 (9): 747–759. DOI: 10.1016/S2213-2600(17)30217-5.Barnes P.J. Role of HDAC2 in the pathophysiology of COPD. Annu. Rev. Physiol. 2009; 71: 451–464. DOI: 10.1146/annurev.physiol.010908.163257.Barnes P.J. Role of HDAC2 in the pathophysiology of COPD. Annu. Rev. Physiol. 2009; 71: 451–464. DOI: 10.1146/annurev.physiol.010908.163257.Hoonhorst S.J.M., ten Hacken N.H.T., Vonk J.M. et al. Steroid resistance in COPD? Overlap and differential antiinflammatory effects in smokers and ex-smokers. PLoS One. 2014; 9 (2): e87443. DOI: 10.1371/journal.pone.0087443.Hoonhorst S.J.M., ten Hacken N.H.T., Vonk J.M. et al. Steroid resistance in COPD? Overlap and differential antiinflammatory effects in smokers and ex-smokers. PLoS One. 2014; 9 (2): e87443. DOI: 10.1371/journal.pone.0087443.Sims M.W., Tal-Singer R.M., Kierstein S. et al. Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: a cross-sectional study. Respir. Res. 2008; 9: 13. DOI: 10.1186/1465-9921-9-13.Sims M.W., Tal-Singer R.M., Kierstein S. et al. Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: a cross-sectional study. Respir. Res. 2008; 9: 13. DOI: 10.1186/1465-9921-9-13.Lebedeva E.S., Kuzubova N.A., Danilov L.N. et al. Experimental modelling of chronic obstructive pulmonary disease. Bull. Exp. Biol. Med. 2012; 152 (5): 659–663. DOI: 10.1007/s10517-012-1601-3.Lebedeva E.S., Kuzubova N.A., Danilov L.N. et al. Experimental modelling of chronic obstructive pulmonary disease. Bull. Exp. Biol. Med. 2012; 152 (5): 659–663. DOI: 10.1007/s10517-012-1601-3.Федин А.Н., Кузубова Н.А., Данилов Л.Н., Лебедева Е.С. Нарушение функции нервных структур дыхательных путей у ингалированных диоксидом азота крыс. Российский физиологический журнал им. И.М.Сеченова. 2007; 93 (9): 1071–1077.Fedin A.N., Kuzubova N.A., Danilov L.N., Lebedeva E.S. [Dysfunction of airway nervous structures in rats inhaled with nitrogen dioxide]. Rossiyskiy fiziologicheskiy zhurnal im. I.M.Sechenova. 2007; 93 (9): 1071–1077 (in Russian).Федин А.Н., Кузубова Н.А., Данилов Л.Н. и др. Бронхолитический эффект преднизолона у крыс, ингалированных диоксидом азота. Российский физиологический журнал им. И.М.Сеченова. 2010; 96 (3): 293–300.Fedin A.N., Kuzubova N.A., Danilov L.N. et al. [Broncholytic effect of prednisolone in the rats inhaled with nitrogen dioxide]. Rossiyskiy fiziologicheskiy zhurnal im. I.M.Sechenova. 2010; 96 (3): 293–300 (in Russian).Кузубова Н.А., Федин А.Н., Лебедева Е.С., Платонова И.С. Влияние различных вариантов терапии на сокращение бронхов крыс с моделированной обструктивной болезнью легких. Российский физиологический журнал им. И.М.Сеченова. 2014; 100 (9): 1049–1058.Kuzubova N.A., Fedin A.N., Lebedeva E.S., Platonova I.S. [Effect of different therapy options on bronchial contraction in rats with modeled obstructive pulmonary disease]. Rossiyskiy fiziologicheskiy zhurnal im. I.M.Sechenova. 2014; 100 (9): 1049–1058 (in Russian).Ueki S., Melo R.C.N., Ghiran I. et al. Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans. Blood. 2013; 121 (11): 2074–2083. DOI: 10.1182/blood-2012-05-432088.Ueki S., Melo R.C.N., Ghiran I. et al. Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans. Blood. 2013; 121 (11): 2074–2083. DOI: 10.1182/blood-2012-05-432088.Ueki S., Tokunaga T., Fujieda S.et al. Eosinophil Etosis and DNA traps: a new look at eosinophilic inflammation. Curr. Allergy Asthma Rep. 2016; 16 (8): 54. DOI: 10.1007/s11882016-0634-5.Ueki S., Tokunaga T., Fujieda S.et al. Eosinophil Etosis and DNA traps: a new look at eosinophilic inflammation. Curr. Allergy Asthma Rep. 2016; 16 (8): 54. DOI: 10.1007/s11882016-0634-5.Uribe Echevarría L., Leimgruber C., Garcia González J. et al. Evidence of eosinophil extracellular trap cell death in COPD: does it represent the trigger that switches on the disease? Int. J. COPD. 2017; 12: 885–896. DOI: 10.2147/COPD.S115969.Uribe Echevarría L., Leimgruber C., Garcia González J. et al. Evidence of eosinophil extracellular trap cell death in COPD: does it represent the trigger that switches on the disease? Int. J. COPD. 2017; 12: 885–896. DOI: 10.2147/COPD.S115969.Snoeck-Stroband J.B., Lapperre T.S., Sterk P.J. et al. Prediction of long-term benefits of inhaled steroids by phenotypic markers in moderate-to-severe COPD: a randomized controlled trial. PLoS One. 2015; 10 (12): e0143793. DOI: 10.1371/journal.pone.0143793.Snoeck-Stroband J.B., Lapperre T.S., Sterk P.J. et al. Prediction of long-term benefits of inhaled steroids by phenotypic markers in moderate-to-severe COPD: a randomized controlled trial. PLoS One. 2015; 10 (12): e0143793. DOI: 10.1371/journal.pone.0143793.Russo P., Tomino C., Santoro A. et al. FKBP5 rs4713916: a potential genetic predictor of interindividual different response to inhaled corticosteroids in patients with chronic obstructive pulmonary disease in a real-life setting. Int. J. Mol. Sci. 2019; 20 (8): pii: Е2024. DOI: 10.3390/ijms20082024.Russo P., Tomino C., Santoro A. et al. FKBP5 rs4713916: a potential genetic predictor of interindividual different response to inhaled corticosteroids in patients with chronic obstructive pulmonary disease in a real-life setting. Int. J. Mol. Sci. 2019; 20 (8): pii: Е2024. DOI: 10.3390/ijms20082024.Cosío B.G., Jahn A., Iglesias A. et al. Haemophilus influenzae induces steroid-resistant inflammatory responses in COPD. BMC Pulm. Med. 2015; 15: 157. DOI: 10.1186/s12890-015-0155-3.Cosío B.G., Jahn A., Iglesias A. et al. Haemophilus influenzae induces steroid-resistant inflammatory responses in COPD. BMC Pulm. Med. 2015; 15: 157. DOI: 10.1186/s12890-015-0155-3.Ito K., Lim S., Caramori G. et al. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc. Natl. Acad. Sci. USA. 2002; 99 (13): 8921–8926. DOI: 10.1073/pnas.132556899.Ito K., Lim S., Caramori G. et al. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc. Natl. Acad. Sci. USA. 2002; 99 (13): 8921–8926. DOI: 10. 1073/pnas.132556899.Kobayashi Y., Wada H., Rossios C. et al. A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3kinase pathway inhibition. Br. J. Pharmacol. 2013; 169 (5): 1024–1034. DOI: 10.1111/bph.12187.Kobayashi Y., Wada H., Rossios C. et al. A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. Br. J. Pharmacol. 2013; 169 (5): 10241034. DOI: 10.1111/bph.12187.Pirina P., Foschino Barbaro M.P., Paleari D., Spanevello A. Small airway inflammation and extrafine inhaled corticosteroids plus long-acting beta2-agonists formulations in chronic obstructive pulmonary disease. Respir. Med. 2018; 143: 74–81. DOI: 10.1016/j.rmed.2018.08.013.Pirina P., Foschino Barbaro M.P., Paleari D., Spanevello A. Small airway inflammation and extrafine inhaled corticosteroids plus long-acting beta2-agonists formulations in chronic obstructive pulmonary disease. Respir. Med. 2018; 143: 74–81. DOI: 10.1016/j.rmed.2018.08.013.Лещенко И.В., Куделя Л.М., Игнатова Г.Л. и др. Резолюция совета экспертов «Место противовоспалительной терапии при ХОБЛ в реальной клинической практике» от 8 апреля 2017 г., Новосибирск. Русский медицинский журнал. 2017; 25 (18): 1322–1324.Leshchenko I.V., Kudelya L.M., Ignatova G.L. et al. [Resolution of the Board of Experts «Place of anti-inflammatory therapy in COPD in real clinical practice» dated April 8th , 2017, Novosibirsk]. Russkiy meditsinskiy zhurnal. 2017; 25 (18): 1322–1324 (in Russian).De Backer J., Vos W., Vinchurkar S. et al. The effects of extrafine beclometasone/formoterol (BDP/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD patients: novel insight using functional respiratory imaging. J. Aerosol. Med. Pulm. Drug Deliv. 2015; 28 (2): 88–99. DOI: 10.1089/jamp.2013.1064.De Backer J., Vos W., Vinchurkar S. et al. The effects of extrafine beclometasone/formoterol (BDP/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD patients: novel insight using functional respiratory imaging. J. Aerosol. Med. Pulm. Drug Deliv. 2015; 28 (2): 88–99. DOI: 10.1089/jamp.2013.1064.Postma D.S., Roche N. Colice G. et al. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9 (1): 1163–1186. DOI: 10.2147/COPD.S68289.Postma D.S., Roche N. Colice G. et al. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9 (1): 1163–1186. DOI: 10.2147/COPD.S68289.Papi A., Vestbo J., Fabbri L. et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018; 391 (10125): 1076–1084. DOI: 10.1016/S0140-6736(18)30206-X.Papi A., Vestbo J., Fabbri L. et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018; 391 (10125): 1076–1084. DOI: 10.1016/S0140-6736(18)30206-X.

The authors declare that there are no conflicts of interest present.